AbCellera Biologics Inc. (ABCL) Free cash flow 2019–2025
AbCellera Biologics Inc. (ABCL) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$174.1MFY2025 · since FY2019: -$1.3M → -$174.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$174.1M | +6.9% |
| FY2024 | -$187.0M | -54.7% |
| FY2023 | -$120.8M | -158.5% |
| FY2022 | $206.7M | +11.1% |
| FY2021 | $186.1M | +1329.9% |
| FY2020 | $13.0M | +1099.0% |
| FY2019 | -$1.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ABCL financial trends
ABCL RevenueABCL Net incomeABCL Net marginABCL Gross profitABCL Gross marginABCL Operating incomeABCL Operating marginABCL Operating cash flowABCL Capital expendituresABCL Return on equityABCL Stock buybacksABCL Dividends paidABCL Total assetsABCL Total liabilitiesABCL Shareholders’ equityABCL overview →